BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 10961860)

  • 1. Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies?
    Reuter CW; Morgan MA; Bergmann L
    Blood; 2000 Sep; 96(5):1655-69. PubMed ID: 10961860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ras processing as a therapeutic target in hematologic malignancies.
    Le DT; Shannon KM
    Curr Opin Hematol; 2002 Jul; 9(4):308-15. PubMed ID: 12042705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ras family signaling: therapeutic targeting.
    Cox AD; Der CJ
    Cancer Biol Ther; 2002; 1(6):599-606. PubMed ID: 12642680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development.
    Rowinsky EK; Windle JJ; Von Hoff DD
    J Clin Oncol; 1999 Nov; 17(11):3631-52. PubMed ID: 10550163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Farnesyltransferase inhibitors in hematologic malignancies: new horizons in therapy.
    Lancet JE; Karp JE
    Blood; 2003 Dec; 102(12):3880-9. PubMed ID: 12920034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of N-myc in neuroblastoma by autocrine IGF-II depends on farnesylated Ras. Application of farnesyltransferase inhibitors.
    Wittrock J; Schweizer P; Girgert R
    Anticancer Res; 2002; 22(6C):4205-9. PubMed ID: 12553057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Ras signaling pathway as a target for farnesyltransferase inhibitors--a new, promising prospects in the treatment for malignant disorders].
    Helbig G; HoĊ‚owiecki J
    Wiad Lek; 2004; 57(9-10):462-7. PubMed ID: 15765763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitors of the ras oncogene as therapeutic targets.
    Ghobrial IM; Adjei AA
    Hematol Oncol Clin North Am; 2002 Oct; 16(5):1065-88. PubMed ID: 12512383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protein farnesyltransferase inhibitors.
    Ayral-Kaloustian S; Salaski EJ
    Curr Med Chem; 2002 May; 9(10):1003-32. PubMed ID: 12733981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of farnesyltransferase inhibitors in hematologic malignancies.
    Santos ES; Rosenblatt JD; Goodman M
    Expert Rev Anticancer Ther; 2004 Oct; 4(5):843-56. PubMed ID: 15485318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical activity of farnesyl transferase inhibitors in hematologic malignancies: possible mechanisms of action.
    Jabbour E; Kantarjian H; Cortes J
    Leuk Lymphoma; 2004 Nov; 45(11):2187-95. PubMed ID: 15512806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies.
    Sebti SM; Hamilton AD
    Oncogene; 2000 Dec; 19(56):6584-93. PubMed ID: 11426643
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The potential of farnesyltransferase inhibitors as cancer chemotherapeutics.
    Gibbs JB; Oliff A
    Annu Rev Pharmacol Toxicol; 1997; 37():143-66. PubMed ID: 9131250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ras farnesyltransferase inhibitors suppress the phenotype resulting from an activated ras mutation in Caenorhabditis elegans.
    Hara M; Han M
    Proc Natl Acad Sci U S A; 1995 Apr; 92(8):3333-7. PubMed ID: 7536929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of SCH 59228, an orally bioavailable farnesyl protein transferase inhibitor, on the growth of oncogene-transformed fibroblasts and a human colon carcinoma xenograft in nude mice.
    Liu M; Bryant MS; Chen J; Lee S; Yaremko B; Li Z; Dell J; Lipari P; Malkowski M; Prioli N; Rossman RR; Korfmacher WA; Nomeir AA; Lin CC; Mallams AK; Doll RJ; Catino JJ; Girijavallabhan VM; Kirschmeier P; Bishop WR
    Cancer Chemother Pharmacol; 1999; 43(1):50-8. PubMed ID: 9923541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pre-clinical development of farnesyltransferase inhibitors.
    Lobell RB; Kohl NE
    Cancer Metastasis Rev; 1998 Jun; 17(2):203-10. PubMed ID: 9770117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The development of protein farnesyltransferase inhibitors as signaling-based anticancer agents.
    Ohkanda J; Blaskovich MA; Sebti SM; Hamilton AD
    Prog Cell Cycle Res; 2003; 5():211-7. PubMed ID: 14593715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Farnesyltransferase inhibitors. Preclinical development.
    Kohl NE
    Ann N Y Acad Sci; 1999; 886():91-102. PubMed ID: 10667207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Farnesyltransferase inhibitors.
    Hahn SM; Bernhard E; McKenna WG
    Semin Oncol; 2001 Oct; 28(5 Suppl 16):86-93. PubMed ID: 11706400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ras farnesyltransferase inhibition: a novel and safe approach for cancer chemotherapy.
    Nammi S; Lodagala DS
    Acta Pharmacol Sin; 2000 May; 21(5):396-404. PubMed ID: 11324435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.